- Home
- AKTX vs PMAX Comparison
AKTX vs PMAX Comparison
Compare AKTX & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- PMAX
- Stock Information
- Founded
- AKTX N/A
- PMAX 2019
- Country
- AKTX United States
- PMAX Hong Kong
- Employees
- AKTX 12
- PMAX N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- PMAX
- Sector
- AKTX Health Care
- PMAX
- Exchange
- AKTX Nasdaq
- PMAX Nasdaq
- Market Cap
- AKTX 35.7M
- PMAX 7.9M
- IPO Year
- AKTX N/A
- PMAX 2024
- Fundamental
- Price
- AKTX $1.14
- PMAX $0.39
- Analyst Decision
- AKTX
- PMAX
- Analyst Count
- AKTX 0
- PMAX 0
- Target Price
- AKTX N/A
- PMAX N/A
- AVG Volume (30 Days)
- AKTX 25.6K
- PMAX 2.1M
- Earning Date
- AKTX 08-18-2025
- PMAX 04-28-2025
- Dividend Yield
- AKTX N/A
- PMAX N/A
- EPS Growth
- AKTX N/A
- PMAX N/A
- EPS
- AKTX N/A
- PMAX N/A
- Revenue
- AKTX N/A
- PMAX $4,694,079.00
- Revenue This Year
- AKTX N/A
- PMAX N/A
- Revenue Next Year
- AKTX N/A
- PMAX N/A
- P/E Ratio
- AKTX N/A
- PMAX N/A
- Revenue Growth
- AKTX N/A
- PMAX N/A
- 52 Week Low
- AKTX $0.85
- PMAX $0.28
- 52 Week High
- AKTX $4.40
- PMAX $4.70
- Technical
- Relative Strength Index (RSI)
- AKTX 43.82
- PMAX N/A
- Support Level
- AKTX $1.10
- PMAX N/A
- Resistance Level
- AKTX $1.18
- PMAX N/A
- Average True Range (ATR)
- AKTX 0.05
- PMAX 0.00
- MACD
- AKTX 0.00
- PMAX 0.00
- Stochastic Oscillator
- AKTX 39.52
- PMAX 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.